(NASDAQ: ALVR) Allovir's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Allovir's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ALVR's revenue for 2024 to be $7,394,703,141, with the lowest ALVR revenue forecast at $7,394,703,141, and the highest ALVR revenue forecast at $7,394,703,141. On average, 1 Wall Street analysts forecast ALVR's revenue for 2025 to be $20,340,574,032, with the lowest ALVR revenue forecast at $20,340,574,032, and the highest ALVR revenue forecast at $20,340,574,032.
In 2026, ALVR is forecast to generate $36,812,124,512 in revenue, with the lowest revenue forecast at $36,812,124,512 and the highest revenue forecast at $36,812,124,512.